论文部分内容阅读
采用５１Ｃｒ释放试验对健康人和骨肉瘤病人外周血单个核细胞（ＰＢＭ）在重组白细胞介素－２（ｒＩＬ－２）条件下，ＬＡＫ细胞的诱导形成及对４种传代瘤细胞的体外杀伤活性进行探讨。实验结果表明：２种来源ＬＡＫ细胞对Ｋ５６２（人慢性髓样红白血病细胞系）、ＳＭＭＣ７７２１（人肝癌细胞系）、ＬＡＸ（人肺腺癌细胞系）的杀伤活性均在５５％以上（按效靶比例５０：１），而对ＯＳ细胞（人骨肉瘤细胞系）的活性普遍低下，杀伤率低于３５％。结果证实：１）健康人和骨肉瘤病人的ＰＢＭ均能在ｒＩＬ－２条件下诱导形成具有广谱抗瘤活性的ＬＡＫ细胞群，二者的杀伤格局和效力相近。２）骨肉瘤细胞本身对ＬＡＫ细胞的杀伤作用存在强烈抗性。
In vitro killing of LAK cells induced by recombinant human interleukin-2 (rIL-2) in peripheral blood mononuclear cells (PBM) from healthy individuals and patients with osteosarcoma using the 51Cr release assay and in vitro killing activity against 4 passaged tumor cells Explore. The experimental results showed that the killing activities of LAK cells from two sources on K562 (human chronic myeloid leukemia cell line), SMMC7721 (human hepatoma cell line), and LAX (human lung adenocarcinoma cell line) were all above 55% (according to The target ratio of 50:1), while the activity of OS cells (human osteosarcoma cell line) is generally low, the killing rate is less than 35%. The results confirmed: 1) PBM in both healthy and osteosarcoma patients can induce LAK cell populations with broad-spectrum anti-tumor activity under the condition of rIL-2, and their killing patterns and efficacy are similar. 2) The osteosarcoma cells themselves have strong resistance to killing LAK cells.